Ravulizumab is indicated in the treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve, or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||24/07/2020|
|Rapid review completed||21/08/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ravulizumab (Ultomiris®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|
|Full pharmacoeconomic assessment commissioned by the HSE||27/08/2020|
|Pre-submission consultation with Applicant||28/06/2021|
|Current Status||Awaiting HTA submission from Applicant|